Startseite Kongressberichte 2019 ESMO World Congress on Gastrointestinal Cancer Session II: Cancer of the Pancreas and Biliary Tract

Session II: Cancer of the Pancreas and Biliary Tract

Reni M, et al.
The conclusion from authors abstract:
DFS by independent review was not significantly improved; however, median DFS in the Gem arm was higher than in historical studies. The interim OS and sensitivity analysis of DFS by the investigator (HR 0.82 for both) were improved for nab-P/Gem compared with Gem. Adjuvant nab-P/Gem was tolerable. The mean QoL scores were initially lower with nab-P/Gem but recovered and differences were never > MID for Gem. Adjuvant nab-P/Gem may be an option for those not eligible for adjuvant FOLFIRINOX; however, the impact of this regimen in the adjuvant setting may be clearer as survival data mature.
Overall, ibrutinib.Nab-P/GCB did not improve OS or PFS for patients with PDAC in the intent-to-treat population. Safety was consistent with known profiles for these agents.
The conclusion from authors abstract:
Patients with a gBRCAm and mPC whose disease had not progressed on PBC derived a statistically significant and clinically meaningful PFS benefit from maintenance olaparib. Olaparib-arm patients were more likely to maintain disease control or achieve a response than those in the placebo arm, and responses were durable lasting a median of more than 2 years.
The conclusion from authors abstract:
Most of the patients had ICC location (64%). The mPFS in the placebo arm is similar according to the tumor location. Despite its exploratory value and the small number of patients per tumor location, regorafenib seemed superior to placebo in ICC, GB, and PH. Data in ECC are not conclusive. Additional biomarkers (FGFR, NGS analysis) are ongoing and will be presented at the meeting.

O-004: Applied Precision Cancer Medicine in advanced biliary tract cancer
Hossein Taghizadeh, et al.
The conclusion from authors abstract:
To our knowledge, this is the first time that the results of genomic sequencing, IHC and FISH were simultaneously analyzed in patients with advanced BTC. Molecular profiling to identify targeted therapy was conducted and therapy recommendations were provided for 12 patients with advanced BTC. Based on our observations, it seems that PCM is a feasible treatment approach for a rare cancer type with limited treatment options.
The conclusion from authors abstract:
HER2-directed targeted therapy represents a novel and tolerable treatment approach for advanced biliary tract cancers harboring somatic HER2 mutations. Given the observed antitumor activity in a patient subset, enrollment will continue to further define the benefit of monotherapy, and ongoing tissue correlates will inform combination strategies to further  enhance responses and outcomes.
See also statements from Gerald Prager, Vienna about two studies presented at ESMO-GI (APACT & POLOand treatment options in the pancreas carcinoma: